Sincalide is a diagnostic agent used to stimulate gallbladder contraction or pancreatic secretion during diagnostic tests, and accelerate fluoroscopy and x-ray examination of the intestinal tract. Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders.
- Mechanism
- Curator reviewed · 1 reference
When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.
- Primary indication
- As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample...Curator reviewed · 4 structured indications
- First approval
- Canada, 2019 · United States, 1976
- Also known as
- CCK C-terminal octapeptide · CCK-8 · Cholecystokinin C-terminal octapeptide
- Code names
- SQ-19844
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Sincalide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account